FluoGuide A/S (FLUO) AI Stock Analysis

• Market Cap: kr582.94M
• Dividend Yield: N/A
• Average Volume (3M): 8.21K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.43
• Revenue Growth: N/A
• EPS Growth: 23.67%
• Country: SE
• Employees: 7
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.96
• Shares Outstanding: 13,620,149
• 10 Day Avg. Volume: 11,579
• 30 Day Avg. Volume: 8,206
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 48 Neutral
• Price Target: kr44.00 ▲(0.00% Upside)

FluoGuide A/S's overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and negative profitability. While technical indicators suggest a bullish trend, the negative valuation metrics due to ongoing losses weigh heavily on the score.

FluoGuide A/S Business Overview & Revenue Model

Company Description

FluoGuide A/S, a life science company, engages in the development and sale of surgical solutions in Denmark. Its lead product candidate is FG001, which is in Phase I/II for the treatment of high-grade glioma, as well as Phase II clinical trial for the treatment of lung cancer. The company also develops FG002, which is in preclinical stage that allows surgeons to differentiate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology. FluoGuide A/S has an agreement with Linköping University Hospital for the development of FG001 that is in the Phase I/II clinical trial for surgical removal of brain cancer; and a collaboration with Copenhagen University Hospital. The company was incorporated in 2018 and is headquartered in Copenhagen, Denmark.

How the Company Makes Money

FluoGuide A/S generates revenue through the development and commercialization of its core technology, which involves the use of fluorescent markers to illuminate cancer cells during surgery. This technology is licensed to hospitals and surgical centers, providing them with an enhanced ability to identify and remove cancerous tissues. The company's revenue model includes sales of its fluorescence-guided surgery products and potential licensing agreements with medical institutions. Additionally, FluoGuide may engage in partnerships with pharmaceutical companies and research institutions to further develop and expand the applications of its technology, potentially leading to milestone payments and royalty streams.

FluoGuide A/S Financial Statement Overview

Summary

FluoGuide A/S is facing significant financial challenges, with declining revenue and negative profit margins. Despite a strong equity position, persistent losses and negative cash flow highlight critical operational inefficiencies.

Income Statement

FluoGuide A/S has been experiencing a significant decline in revenue over the years, with a drastic decrease from 2021 to 2024. The gross profit margin remains high, indicating that the company is able to cover its direct costs despite low revenues. However, the net profit margin is negative, reflecting substantial net losses. The EBIT and EBITDA margins are also negative, highlighting ongoing operational challenges and inefficiencies.

Balance Sheet

The balance sheet shows a strong equity position compared to liabilities, indicating financial stability. The debt-to-equity ratio has improved due to reduced debt levels, which is positive for financial health. However, the company has been consistently reporting net losses, which impacts return on equity adversely. The equity ratio remains strong, demonstrating a solid cushion against liabilities.

Cash Flow

The company continues to face negative free cash flow, indicating cash outflows are exceeding inflows. The operating cash flow to net income ratio is concerning, suggesting operational inefficiencies. Despite substantial financing activities, the free cash flow remains negative, which may necessitate further external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-641.00K	385.00K	423.00K	6.51M	9.61M	0.00
Gross Profit	-641.00K	385.00K	423.00K	6.51M	9.61M	0.00
EBITDA	-35.32M	-32.81M	-43.90M	-32.21M	-28.65M	-22.04M
Net Income	-32.04M	-28.96M	-38.38M	-27.34M	-23.77M	-17.46M
Balance Sheet
Total Assets	33.40M	28.38M	29.61M	35.62M	53.31M	16.74M
Cash, Cash Equivalents and Short-Term Investments	19.63M	18.61M	21.67M	26.01M	46.76M	10.64M
Total Debt	22.83M	624.00K	10.83M	205.00K	57.00K	218.00K
Total Liabilities	27.45M	5.31M	16.89M	3.65M	14.61M	12.33M
Stockholders Equity	5.95M	23.07M	12.72M	31.97M	38.70M	4.41M
Cash Flow
Free Cash Flow	-30.62M	-30.00M	-31.81M	-37.71M	-15.06M	-8.85M
Operating Cash Flow	-30.62M	-29.15M	-31.81M	-37.65M	-15.06M	-8.85M
Investing Cash Flow	-49.00K	-987.00K	-37.00K	-117.00K	0.00	-42.00K
Financing Cash Flow	21.35M	27.08M	27.50M	17.02M	51.18M	17.18M

FluoGuide A/S Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 44.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:FLUO, the sentiment is Positive. The current price of 44 is above the 20-day moving average (MA) of 42.02, above the 50-day MA of 40.72, and above the 200-day MA of 41.94, indicating a bullish trend. The MACD of 1.24 indicates Negative momentum. The RSI at 52.44 is Neutral, neither overbought nor oversold. The STOCH value of 42.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:FLUO.

FluoGuide A/S Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FLUO	48 Neutral	kr582.94M	―	―	―	―	23.67%
NANEXA	44 Neutral	€305.97M	―	-34.87%	―	-38.56%	69.37%
ACE	43 Neutral	€357.62M	―	-133.47%	―	―	9.40%
QLINEA	41 Neutral	€173.48M	―	-330.10%	―	16.98%	50.52%
IRLAB.A	38 Underperform	€209.37M	―	-502.37%	―	82.14%	11.89%
GUARD	32 Underperform	€459.82M	―	-159.75%	―	―	-20.61%